A protein-based COVID-19 vaccine is currently used in more than 40 countries in individuals older than 18 years and has been approved by European Medicines Agency for use in individuals aged 12 years and older. The World Health Organization suggests that it can be offered to patients with previous SARS-CoV-2 infection; however, it should not be given to patients with acute illness, including those with a body temperature of 38.5 °C (101.3 °F). Polyethylene glycol (PEG), an ingredient in mRNA vaccines, is not present in the protein-based vaccine. Thus, it is safe for use in patients with PEG allergy. The current recommended dosing regimen is two doses administered 3-8 weeks apart.
Learn more about COVID-19 vaccines.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Glenn Wortmann. Fast Five Quiz: COVID-19 Vaccines - Medscape - Aug 02, 2022.